{
  "symbol": "AMGN",
  "year": 2022,
  "period": "Y2022",
  "curated_text": "Symbol: AMGN. Year: 2022. Period: Y2022. ReportType: K10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Celgene Celgene Corporation CGRP, CHMP Committee for Medicinal Products for Human, CIT, CMS Centers for, Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19, CV, DaVita DaVita Inc., EC European Commission, EMA European Medicines Agency, EPS, ERG, ESA, ESG, ESRD, EU European Union FASB Financial Accounting Standards Board, FDA U.S. Food and Drug Administration FDCA Federal Food, Drug, Cosmetic Act FGFR2b, Fitch Fitch Ratings, Inc. ii, Management Board, Puerto Rico FTC Federal Trade Commission, GDPR General Data Protection. Context excerpt: Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice DoR duration of response EC European Commission EMA European Medicines Agency EPS earnings per share ERG employee resource group ESA erythropoiesis-stimulating agent ESG environmental, social and governance ESRD end-stage renal disease EU European Union FASB Financial Accounting Standards Board FCPA U.S. Foreign Corrupt Practices Act FDA U.S. Food and Drug Administration FDCA Federal Food, Drug, and Cosmetic Act FGFR2b fibroblast growth factor receptor 2b Fitch Fitch Ratings, Inc. ii Term Descr",
  "competition_summary": [
    {
      "competitor": "Celgene Celgene Corporation CGRP",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "CHMP Committee for Medicinal Products for Human",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "CIT",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "CMS Centers for",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "CV",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "DaVita DaVita Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "EC European Commission",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "EMA European Medicines Agency",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "EPS",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "ERG",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "ESA",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "ESG",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "ESRD",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "EU European Union FASB Financial Accounting Standards Board",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "FDA U.S. Food and Drug Administration FDCA Federal Food, Drug",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "Cosmetic Act FGFR2b",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "Fitch Fitch Ratings, Inc. ii",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "Management Board",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "Puerto Rico FTC Federal Trade Commission",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    },
    {
      "competitor": "GDPR General Data Protection",
      "mentions": 1,
      "context": "Competition and Innovation Act of 2009 Celgene Celgene Corporation CGRP calcitonin gene-related peptide chemotherapy anticancer medicines CHMP Committee for Medicinal Products for Human Use CIT chemotherapy-induced thrombocytopenia CKD chronic kidney disease CMS Centers for Medicare & Medicaid Services COSO Committee of Sponsoring Organizations of the Treadway Commission COVID-19 coronavirus disease 2019 CV cardiovascular DaVita DaVita Inc. DLL3 delta-like ligand 3 DOJ U.S. Department of Justice"
    }
  ]
}